Future growth expected to be limited for the company. Persisting conditions could become a barrier for current share price levels, reflected in Jianzhijia Pharmaceutical Chain Group's lower P/E ratio due to slower forecast growth.
Analysts say Jianzhijia Pharmaceutical Chain Group's stock is underpriced and its future profits aren't factored into the current price. Low price-to-earnings ratio and potential earnings growth make it a good investment.
Yunnan Jianzhijia Health-Chainに関するコメント
まだコメントはありません